

hydrix[®]

**Improve
a billion
lives**





Growth through
medtech innovation

Building on 20 years of medtech product innovation



Sales & Distribution



Identifying and distributing
high growth medtech
products

Product Innovation



Transforming ideas into
commercial products



Venture Investment

Investing in
early-stage high potential
medical device companies



Our strategic focus

**Improve
cardiovascular
disease (CVD)
management
& outcomes**

CVD is the

No 1 Cause of death globally

18million

Annual global
CVD related
deaths ¹

85%

CVD deaths
caused by heart
attacks or stroke ¹


\$70B+

CVD device
market by 2027 ²



Our objective

**Three or more
CVD devices
producing
+\$50m
revenues p.a.
in 2025**



Meeting our objective of becoming a global medtech product company will reshape our revenue mix and earnings.



Realising our objective

Progressing product launches in CY22



Product 1

Implantable Monitoring Device

AngelMed Guardian

FDA approved implantable continuous heart monitor

- 45% of heart attacks are silent
- <1 hour surgery, like a pacemaker implant
- Significantly reduces false positive hospital visits



Product 2

Cardiovascular Surgery Device

Phyzhon FFR

Coronary guidewire with integrated pressure sensor

- Improve stent placement procedures
- Better patient experience
- Reduces treatment time

Small percentage market capture could deliver A\$50m+ revenues p.a.



Future product expansion

We are evaluating several new opportunities to build on our product portfolio



FY21 & YTD FY22 Highlights

Advancing our global medtech strategy

Despite COVID causing many disruptions & delays, we achieved significant milestones. Highlights from FY21 and YTD FY22 include:

- Delivered FY21 **\$7.5m** revenues
- Achieved **FIRST** ever sales and implants of the AngelMed Guardian
- Signed **SECOND** exclusive cardiac device distribution agreement
- Submitted regulatory approvals in **FIVE** jurisdictions for AngelMed Guardian
- **Appointed** several senior sales & business development personnel
- Appointed **Mr Paul Lewis** as Non-Executive Director
- Recapitalised the company, paying down **\$4.5m** debt
- Received **FOUR** International Good Design Awards
- A growing international market recognition & presence



Hydrix is fast emerging as a global medtech company



CY22 Outlook

Progressing towards first commercial product sales

CY22 key milestone news flow beginning the first half:

- **Outcome** of an Australian Human Ethics Committee review of The Guardian (*in progress*)
- **Outcomes** of AngelMed Guardian TGA (AUS) and HSA (SNG) regulatory approval process
- **First** sales & implants of AngelMed Guardian in Australia, Singapore & New Zealand
- **Commence** First-in-Human Trials of Phyzhon cardiac catheter guidewire
- **Appoint** SE Asia sub-distributors for AngelMed Guardian and **outcomes** of regulatory approvals for Malaysia, Hong Kong, Thailand
- Client services YTD revenue trending to YoY **growth +40%**
- **Cash inflow** of ~\$2.3m if HYD \$0.12c options are exercised
- **Uplift** in valuations across the Ventures portfolio



Summary

Building a global medtech company by 2025

World class team
focused on
improving
a billion lives

Product sales
into the
US \$70B
CVD market
commencing
CY2022

Board &
management
with a
**proven track
record**



**Improving a
billion lives**





Disclaimer

This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to investors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of the Company. The document is not intended to constitute an invitation or an inducement to engage in any investment activity. The presentation is not intended to constitute investment advice and should not be relied upon as such. This document is not intended as an offer or recommendation with respect to the purchase or sale of any securities in the Company.

The content and graphical illustrations contained in the presentation are provided for information purposes and should not be relied upon to form any investment decisions or to predict future performance. The Company is wholly reliant upon third parties for the accuracy and completeness of the information in the presentation and has no duty of care owed to you in relation to such information. Although the information expressed is provided in good faith and the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved. Important factors that could cause actual results to differ materially from those included in the forward-looking statements include amongst others, unforeseen delays in product development, the timing and extent of any changes in the associated technology and the ability of the Company to meet its stated business goals.

Prospective investors should make their own independent evaluation of an investment in the Company or seek advice from their financial adviser, accountant, lawyer, stockbroker or other professional adviser before making any investment decision. Nothing in this presentation should be construed as financial product advice, whether personal or general, for the purposes of Section 766B of the Corporations Act, or otherwise. This presentation does not amount to, involve or imply a recommendation or a statement of opinion in respect of whether to buy, sell or hold a financial product.

Neither Hydrix nor any of its or their associates or any of the Company’s directors’ (Hydrix Group) shall have any liability whatsoever for: (a) investment advice; (b) a recommendation to enter into any transaction or strategy; (c) advice that a transaction or strategy is suitable or appropriate; (d) the primary basis for any investment decision; (e) a representation, warranty, guarantee with respect to the legal, accounting, tax or other implications of any transaction or strategy; or (f) to cause the Hydrix Group to be an advisor or fiduciary of any recipient of this report or other third party. None of the Hydrix Group shall be responsible for or have any liability to you for losses or damages (whether consequential, incidental or otherwise) arising in any way for errors or omissions in, or the use of or reliance upon the information contained in this document. To the greatest extent permitted by law, we exclude all conditions and warranties that might otherwise be implied by law with respect to the document, whether by operation of law, statute or otherwise, including as to their accuracy, completeness or fitness for purpose. Unauthorised copying of this document is prohibited.